Reengineering glycyrrhetinic acid into a therapeutic oligomer for targeted tumor therapy with cardioprotection

Le résumé fourni par la source

To overcome the inherent limitations of conventional nanocarriers such as therapeutic inefficacy and suboptimal drug loading capacity, a novel "polymeric nanodrug" strategy was developed. This approach redefines nanodrug design by employing glycyrrhetinic acid (GA) simultaneously as a bioactive agent and a polymerizable targeting monomer to synthesize poly-glycyrrhetinic acid (PGA), achieving near-theoretical drug loading approaching 100%. Subsequent PEGylation yielded hepatocellular carcinoma (HCC)-targeting PGA-PEG-GA nanodrugs, which exhibited a 1.89-fold enhancement in antitumor efficacy compared to free GA. The exceptionally low critical micelle concentration (CMC) of PGA-PEG-GA enables efficient encapsulation of additional therapeutics. Using doxorubicin (DOX) as a model drug, HCC-targeting nanodrugs (denoted as DOX@PGA-PEG-GA NDs) were fabricated. In vitro studies demonstrated that the nanodrugs induced 2.5-fold higher toxicity in tumor cells than normal cells, enhanced cellular uptake by 3.0-fold, and reduced DOX-induced cardiomyocyte apoptosis by 54%. In vivo evaluations revealed a tumor inhibition rate of 89.7 ± 5.2% for DOX@PGA-PEG-GA NDs and 40.09 ± 11.94% for blank PGA-PEG-GA NDs, together with 18.3-fold higher intra-tumoral accumulation compared to free DOX and complete mitigation of DOX-related cardiotoxicity. This integrated "structure-function-safety" strategy effectively overcomes critical challenges in drug-loading efficiency and functional synergy, offering a robust and novel platform for targeted nanodrug applications.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.